Comparative Pharmacology
Head-to-head clinical analysis: COLOCORT versus CORTIFOAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COLOCORT versus CORTIFOAM.
COLOCORT vs CORTIFOAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Colocort (hydrocortisone acetate) is a corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators such as prostaglandins and leukotrienes, and suppression of immune responses.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
10 mg rectally administered once daily, preferably at bedtime, as a retention enema.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
None Documented
None Documented
Terminal elimination half-life: 2.5–3.5 hours (mean ~3 hours). No active metabolites, so duration of action correlates with half-life.
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Renal: ~30% as metabolites; fecal/biliary: ~20% as metabolites; remainder metabolized with minimal unchanged drug excreted.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Category C
Category C
Corticosteroid
Corticosteroid